ARCHIVES

Analysis Reveals Patient Subset With Lower PFS in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

Politics May Play Role In FDA’s Avastin Decision

May 27, 2011

The Clinical Trials Working Group: NCI panel considers plan to centralize clinical trial review and prioritization. NCI director faults system for duplication, “equivocal results.”

August 13, 2004

Upper Endoscopy Most Effective When Performed in 3-Year Intervals

July 27, 2012

Guideline Adherence Improves Early Breast Cancer Survival

August 27, 2004

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

November 28, 2014

NCAB Committee Submits Drafts Of QRA Policy Statement

July 8, 1983